<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Newsroom

Press Releases

Our latest announcements

Biodesix Closes Series D Financing

Biodesix has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for VeriStrat.

Biodesix Announces New VeriStrat® Data to be Presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

Results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Biodesix Appoints Vice President of Clinical Development & Medical Affairs

Biodesix announced the appointment of Dominic Spinella, Ph.D., as Vice President of Clinical Development & Medical Affairs.

Biodesix’ Proteomic Analysis of Innovative Immunotherapy Clinical Trial in Pancreas Cancer presented at European Society of Medical Oncology’s (ESMO) World Congress on Gastrointestinal Cancer

The first presentation of data resulting from a corporate partnership to explore development of a new diagnostic test based on Biodesix’ technology.

Biodesix’ Paul Beresford Joins 2012 BIO Panel for Personalized Medicine Commercialization

Biodesix’ Paul Beresford will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine.

VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer

VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.

Biodesix Announces Phase 3 Clinical Trial Collaboration with Kadmon

Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).

Biodesix Relocates to Boulder, CO

Biodesix, Inc., today announced the relocation of their corporate headquarters from Broomfield, Colorado to Boulder, Colorado.

Biodesix Receives New EU and US Patents for Blood-based Oncology Tests

Biodesix announced the issuance of three additional patents. Two which provide intellectual property protection and the other for Veristrat.

VeriStrat® Test Predicts Outcomes in Advanced Breast Cancer Patients

Veristrat can be used to identify a group of patients with worse progression-free (PFS) when treated with Femera alone, independent of Her2 status.